Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol

Infection. 2025 Jun;53(3):1227-1231. doi: 10.1007/s15010-024-02404-9. Epub 2024 Oct 7.

Abstract

Cefiderocol is a new siderophore-beta-lactam antibiotic used for the treatment of severe multidrug-resistant infections like sepsis, hospital-acquired and ventilator-associated pneumonia in adults, but there are only single reports on its use in the neonatal population. We describe the successful cefiderocol treatment of a newborn with pneumogenic sepsis due to Stenotrophomonas maltophilia.

Keywords: Stenotrophomonas maltophilia; Cefiderocol; Multi drug resistance; Neonate; Pneumogenic sepsis.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents* / therapeutic use
  • Cefiderocol
  • Cephalosporins* / therapeutic use
  • Cross Infection* / drug therapy
  • Cross Infection* / microbiology
  • Female
  • Gram-Negative Bacterial Infections* / drug therapy
  • Gram-Negative Bacterial Infections* / microbiology
  • Healthcare-Associated Pneumonia* / drug therapy
  • Healthcare-Associated Pneumonia* / microbiology
  • Humans
  • Infant, Newborn
  • Pneumonia, Bacterial* / drug therapy
  • Pneumonia, Bacterial* / microbiology
  • Stenotrophomonas maltophilia* / drug effects
  • Stenotrophomonas maltophilia* / isolation & purification
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Cefiderocol
  • Cephalosporins